Advertisement
U.S. markets open in 3 hours 42 minutes

Moleculin Biotech, Inc. (MBRX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
5.54+0.86 (+18.38%)
At close: 04:00PM EDT
5.37 -0.17 (-3.07%)
After hours: 07:55PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.68
Open4.80
Bid5.36 x 100
Ask5.63 x 100
Day's Range4.75 - 5.69
52 Week Range4.34 - 24.75
Volume88,464
Avg. Volume30,505
Market Cap12.34M
Beta (5Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MBRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Moleculin Biotech, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    2 years agoMorningstar
View more